CCM
MRNA icon

Crossvault Capital Management’s Moderna MRNA Stock Holding History

Crossvault Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$3.28M Sell
22,979
-950
-4% -$136K 1.29% 26
2022
Q1 		$4.12M Sell
23,929
-2,283
-9% -$384K 1.33% 27
2021
Q4 		$6.66M Buy
26,212
+3,279
+14% +$959K 2% 22
2021
Q3 		$8.83M Buy
22,933
+4,258
+23% +$1.57M 2.78% 14
2021
Q2 		$6.6M Buy
18,675
+3,290
+21% +$588K 2.01% 24
2021
Q1 		$2.02M Buy
+15,385
New +$2.23M 0.72% 38

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Crossvault Capital Management's MRNA Position: Q2 2022 in Review

Crossvault Capital Management reduced its Moderna (MRNA) stake by 4% in Q2 2022, selling an estimated $136K and leaving 22,979 shares worth $3.28M. The position accounts for 1.29% of the portfolio, ranked #26.

Crossvault Capital Management first reported a position in MRNA in Q1 2021 and has held it in 6 quarters since. The position peaked at $8.83M in Q3 2021. 981 funds tracked by Wall St. Rank hold MRNA as of Q2 2022.

  • Crossvault Capital Management held 22,979 shares of Moderna worth $3.28M as of Q2 2022.
  • Crossvault Capital Management sold 950 Moderna shares in Q2 2022, an estimated $136K.
  • Moderna made up 1.29% of Crossvault Capital Management's portfolio in Q2 2022, its #26 holding.
  • Crossvault Capital Management first reported a position in Moderna in Q1 2021 and has held it in 6 quarters since.
  • Crossvault Capital Management's Moderna position peaked at $8.83M in Q3 2021.
  • 981 funds tracked by Wall St. Rank held Moderna as of Q2 2022.

Based on Crossvault Capital Management's 13F filing for Q2 2022, filed 8 Aug 2022.